Analysts Set Alphatec Holdings, Inc. (NASDAQ:ATEC) Price Target at $17.89

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the nine analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $17.89.

A number of equities research analysts have issued reports on ATEC shares. Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 target price on shares of Alphatec in a research report on Friday, May 2nd. HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. Barclays boosted their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 22nd. StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Finally, Piper Sandler reissued an "overweight" rating and set a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research report on Friday, May 2nd.

Insiders Place Their Bets

In related news, EVP David Sponsel sold 33,732 shares of the business's stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $10.83, for a total value of $365,317.56. Following the sale, the executive vice president now owns 668,977 shares of the company's stock, valued at $7,245,020.91. The trade was a 4.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Scott Lish sold 12,000 shares of the stock in a transaction on Monday, May 5th. The stock was sold at an average price of $12.12, for a total value of $145,440.00. Following the transaction, the chief operating officer now owns 826,251 shares of the company's stock, valued at $10,014,162.12. This represents a 1.43 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 126,945 shares of company stock worth $1,416,352. 22.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Alphatec

Hedge funds have recently made changes to their positions in the company. Corton Capital Inc. bought a new stake in Alphatec during the first quarter worth about $143,000. LPL Financial LLC increased its holdings in Alphatec by 1.2% during the 1st quarter. LPL Financial LLC now owns 418,061 shares of the medical technology company's stock valued at $4,211,000 after purchasing an additional 4,826 shares in the last quarter. Royce & Associates LP raised its position in Alphatec by 14.3% in the 1st quarter. Royce & Associates LP now owns 1,147,979 shares of the medical technology company's stock valued at $11,641,000 after purchasing an additional 143,478 shares during the last quarter. Legato Capital Management LLC acquired a new position in Alphatec in the first quarter worth $600,000. Finally, Larson Financial Group LLC bought a new stake in shares of Alphatec during the first quarter worth $54,000. Institutional investors and hedge funds own 66.35% of the company's stock.

Alphatec Stock Down 0.9 %

NASDAQ ATEC traded down $0.11 during trading on Friday, reaching $12.34. The company's stock had a trading volume of 365,151 shares, compared to its average volume of 2,112,021. The business has a 50-day moving average price of $10.48 and a 200-day moving average price of $10.00. Alphatec has a 1-year low of $4.88 and a 1-year high of $12.79. The stock has a market capitalization of $1.80 billion, a PE ratio of -9.64 and a beta of 1.06. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. During the same quarter in the prior year, the company posted ($0.34) earnings per share. The company's revenue for the quarter was up 22.2% on a year-over-year basis. On average, research analysts forecast that Alphatec will post -1.08 earnings per share for the current fiscal year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.